(Shared Conference with World Preclinical Congress and IO Pharma Congress)

Cambridge Healthtech Institute’s 8th Annual

Preclinical Strategies, Models & Tools in Oncology

Advancing Translation in Oncology and Immuno-Oncology

June 18-19, 2019

The rise of cancer immunotherapy instigated a wide range of unique preclinical and translational challenges. The demand for predictive and robust preclinical models and approaches to minimize translational failures in immuno-oncology is at an all-time high. The need for leveraging phenotypic features of models, for early identification of predictive biomarkers, for rational design of combination therapies, and for researching the cancer-immune cell interactions add to the complexity of translational research in immuno-oncology. Cambridge Healthtech Institute’s Eighth Annual Preclinical Strategies, Models & Tools in Oncology conference is designed as a forum for ideas and opinions exchange on how to decrease the rate of clinical failures in oncology and immuno-oncology.


BiTE Preclinical and Translational Programs: Strategy and Lesson Learned

Matthias Friedrich, PhD, Scientific Director, Nonclinical Development, Amgen

COBRA: A Novel Conditionally Active Bispecific Antibody that Regresses Established Solid Tumors in Mice

Chad May, PhD, Vice President, Research and Development, Maverick Therapeutics

Applying Preclinical Immuno-Oncology Mouse Models to Guide Combination Strategies in the Clinic

Elaine Pinheiro, PhD, Principal Scientist, Cancer Immunotherapy, Merck


In vivo CRISPR Screen to Identify Immune Modulators in Tumor Cells

Zhao Chen, PhD, Investigator III, Exploratory Immuno-Oncology, Novartis Institutes for BioMedical Research

Preclinical and Translational Imaging Methods in the Development of Immuno-Oncology Therapeutics

Charles Glaus, PhD, Director, Translational Research & Early Clinical, Takeda


PANEL DISCUSSION: Partnering, Preclinical Strategies and Tools, IO Clinical Trials; Capital Invested in IO Relative to Other Oncology Areas

Moderator: Leigh Zawel, PhD, CSO, Cullinan Oncology

Michael Woo, Director, Head of Immuno-Oncology Search & Evaluation, External Innovation, EMD Serono, Inc.
Sybil Williams, PhD, Director, Biology Oncology Discovery, Merck
Paul Young, PhD, Executive Director, Business Development & Licensing, Merck
Christine Borowski, PhD, Entrepreneur in Residence, Appletree Ventures

  • Has the IO bubble popped? Why have no other IO drugs emerged with PD1/PDL1-like efficacy?
  • What combination strategies are being explored to convert poorly PD1 responsive tumors to more responsive ones?
  • Are there new IO monotherapies or combos that appear promising?
  • Is patient stratification practical with IO therapies?
  • What partnering strategies are most effective?
  • What is a recent deal your firm signed that you’re excited about?

For more details on the conference, please contact:
Marina Filshtinsky, MD
Executive Director, Conferences
Cambridge Healthtech Institute
Phone: 781-972-5496
Email: mfilshtinsky@healthtech.com

For partnering and sponsorship information, please contact:

Companies A-K
Rod Eymael
Business Development Manager
Cambridge Healthtech Institute
Phone: 781-247-6286
Email: reymael@healthtech.com

Companies L-Z
Joseph Vacca, M.S.
Director, Business Development
Cambridge Healthtech Institute
Phone: 781-972-5431
Email: jvacca@healthtech.com